The Pharma Data

JANUARY 4, 2021

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc.

Therapies 52

Therapies Virus Disease Licensing 52

Drug Target Review

SEPTEMBER 22, 2023

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. 5 Organoids are recognised as New Alternative Methods (NAMs) in drug development.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

Drug Target Review

DECEMBER 5, 2024

Viral vectors have been crucial in transforming the gene therapy landscape due to their natural ability to infect cells. 1 In 2017, the US Food and Drug Administration (FDA) approved the first AAV-based gene replacement therapy (Luxturna), for Leber congenital amaurosis type 2.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

JANUARY 12, 2021

In December, life sciences giant Bayer launched a cell and gene therapy platform within its pharmaceutical division in order to become a leading company within a rapidly emerging and evolving field that offers the potential of life-saving therapies. Photo courtesy of Bayer.

Therapies 52

Therapies Licensing Licensing Pharmaceuticals 52

Drug Target Review

JUNE 21, 2023

Enabling the systematic discovery of these largely uncharted targets can be a valuable opportunity for development of novel therapies. Genetic-based therapeutics hold significant promise in the clinic Despite the growing number of genes linked to human disease, the proportion of genes targeted by approved therapies remains low.

Disease 111

Disease Clinical Trials Therapies Science 111

Creative Biolabs

JUNE 29, 2023

At present, a large number of G protein-coupled receptor-targeted drugs have been marketed, and a large number of drugs are under development. GPCR is the most valuable target for drug development, and more drugs will be used to treat various diseases in the future.

Therapies 52

Therapies Small Molecule Drugs Drug Development 52

Drug Target Review

SEPTEMBER 26, 2023

Early detection of neurotoxicity induced by potential new therapies is a major challenge, and hiPSC-neuronal cells may provide a solution. CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact. 2017 Jan;155(1):234–47.

Drugs 111

Drugs FDA Disease Animal Testing 111

Advarra

AUGUST 16, 2022

In 2016, the FDA granted 333 (57%) of the 582 orphan drug designation requests it received – nearly 10 times the number of designations the agency awarded in 1986. The agency’s 2019 guidance, Rare Diseases: Common Issues in Drug Development , called attention to the need for natural history studies for rare diseases.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

Drug Target Review

MAY 23, 2023

Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.

Drugs 75

Drugs Small Molecule Production Disease 75

Drug Target Review

OCTOBER 24, 2023

We also believe that drug development teams should routinely consider the potential modifying effect of the gut microbiome on drug potency and factor it into assessments of PK and PD. MB097, our drug with immune-oncology applications, is a consortium of nine bacterial strains. difficile and C. albicans.

Treatment 122

Treatment Pharmaceuticals Pharmacokinetics Trials 122

Vial

DECEMBER 5, 2023

It has become a fundamental tool for researchers to explore the complexities of genetic information and conduct genetic-informed drug development. Sponsors have used NGS to screen patients for clinical trial eligibility and patient stratification , expanded CDx development, and comprehensive genomic profiling (CGP).

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52

The Pharma Data

OCTOBER 21, 2020

In 2017, the most recent year for data in the U.S., Roughly one in three people initially diagnosed in the early stages of the disease go on to develop recurrent advanced or metastatic breast cancer. Daiichi Sankyo is not only partnering with advocacy groups, but is also developing treatments for this common disease.

Disease 52

Disease Therapies Treatment Drug Development 52

New Drug Approvals

SEPTEMBER 13, 2024

4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] 12] Positron emission tomography imaging revealed that brain KORs were almost completely saturated by the drug 2.5 Dhir A (January 2017). August 2017.

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

The Pharma Data

JUNE 25, 2021

Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (A?) Breakthrough Therapy designation is an FDA program intended to expedite the development and review of medicines for serious or life-threatening conditions.

Disease 40

Disease Treatment Therapies FDA 40

Drug Target Review

JULY 10, 2023

This deeper understanding has enabled the development of numerous potentially breakthrough therapies, which are currently being tested in the clinic. As scientists continue to elucidate and advance novel drug targets and technology applications, the goal of bringing impactful treatments to patients becomes more of a reality.

Research 52

Research Disease Treatment Drug Development 52

Drug Target Review

OCTOBER 25, 2024

Biomarkers are an essential advancement that will help determine risk for developing Alzheimer’s disease, diagnose the disease before symptoms have progressed significantly, predict how quickly patients may experience cognitive decline and evaluate how well new therapies are working. 2017, February 4). link] Cummings J.

Disease 59

Disease Clinical Trials Therapies Science 59

DrugBank

JUNE 27, 2023

The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care. Drug Discov.

Disease 98

Disease Treatment Drugs Clinical Trials 98

The Pharma Data

DECEMBER 8, 2020

Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost. Silverback Therapeutics

RNA 52

RNA Therapies Disease Protein Expression 52

NIH Director's Blog: Drug Development

JULY 20, 2017

Helping to fuel this optimism are preliminary results released this week from early-stage clinical trials of three next-generation, triple combination therapies that modulate the function of CFTR. Developing drugs that could rescue the function of mutant CFTR has been a long and difficult journey. 1989 Sep 8;245(4922):1059-1065.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Disease 52

NIH Director's Blog: Drug Development

DECEMBER 4, 2018

This blood vessel-tissue interface can prevent certain molecules—including some potentially beneficial therapies—from entering the brain. It included a chip that models the blood-brain barrier. I’ll be anticipating some some really cool science results in the coming months!

Science 52

Science International Laboratories Research 52

The Pharma Data

AUGUST 21, 2020

Eli Lilly, on the heels of detailing a clinical win in China for PD-1 inhibitor Tyvyt, has decided to take a bigger stake in the drug developed by partner Innovent Biologics in an expanded deal that could vault it into the lucrative—yet ultra-competitive—U.S. lung cancer market. approval, potentially speeding time to market.”.

Licensing 52

Licensing Licensing FDA Therapies 52

The Pharma Data

OCTOBER 26, 2020

(Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Fast Track designation allows for early and frequent communication with the FDA throughout the entire drug development and review process.

Disease 40

Disease FDA Treatment Therapies 40

The Pharma Data

DECEMBER 9, 2020

333-222268) previously filed with the Securities and Exchange Commission (the “SEC”) on December 22, 2017 and declared effective by the SEC on January 5, 2018. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. SAN DIEGO, Dec.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Treatment 52

Alta Sciences

JUNE 27, 2023

They remind us of the immense benefits of drug development. For Michelle Newby, Study Coordinator II for preclinical services at Altasciences, research strikes a personal chord: In 2017, at the age of 25, Michelle was diagnosed with cancer. A: In December of 2017, I was diagnosed with two different types of stage III leukemia.

Clinical Trials 40

Clinical Trials Trials Treatment Science 40

The Pharma Data

JANUARY 31, 2021

Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. CEPI has initiated 11 partnerships to develop vaccines against the novel coronavirus.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

A Dose of Drug Development

SEPTEMBER 17, 2018

How Integrium as a company plays a role in advanced technology such as these is that Integrium has the advantage of having 20 years of experience with variety of therapies within its portfolio. Though 2017 may have had more IPOs in 9 months of the year, but the capital raise is considerably different.

Marketing 40

Marketing Therapies 40

The Pharma Data

JANUARY 25, 2021

26, 2021 /PRNewswire/ — Dynacure , a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the U.S. 2017 Jun 7 ;8:15661. STRASBOURG, France and PHILADELPHIA , Jan. Patent No.

Treatment 40

Treatment Disease Pharmaceuticals FDA 40

Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. Importantly, midomafetamine was proposed for use in conjunction with psychotherapy.

FDA 40

FDA Trials Therapies Regulations 40

The Pharma Data

DECEMBER 3, 2020

Trimer-Tag © is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. Additionally, Clover is leveraging its in-house GMP biomanufacturing capabilities to support large-scale production of its biologic therapies. S-Trimer is intended to be adjuvanted. About CEPI.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

FEBRUARY 18, 2022

Nirsevimab has been granted regulatory designations to facilitate expedited development by several regulatory agencies around the world. In March 2017, AstraZeneca and Sanofi announced an agreement to develop and commercialise nirsevimab.

Virus 40

Virus Trials Disease Clinical Trials 40

The Pharma Data

JULY 29, 2021

today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) — granted Breakthrough Therapy designation by the U.S. and slowed clinical decline in an 18-month Phase 2b proof of concept study (Study 201, n=856) in early AD ( Alz Res Therapy 13; 2021 ).

Clinical Trials 52

Clinical Trials Treatment Disease Clinical Development 52

The Pharma Data

APRIL 25, 2021

1 7 Passive immunization could offer rapid protection unlike active immunization, which can take weeks to develop protection. In March 2017, AstraZeneca and Sanofi announced an agreement to develop and commercialize nirsevimab. Lancet 2017; 390: 946–58. Respiratory Syncytial Virus Seasonality — United States, 2014–2017.

Virus 40

Virus Trials Disease Hospitals 40

The Pharma Data

JANUARY 31, 2021

Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. About CpG 1018.

Vaccine 52

Vaccine Trials Virus RNA 52

Codon

APRIL 9, 2024

falciparum to monotherapy with conventional drugs like chloroquine and sulfadoxine-pyrimethamine, that the WHO recommended treating malaria with drugs in combination with artemisinin. Department of Defense administered mefloquine, the synthetic drug developed at Walter Reed in the U.S.,

Drugs 137

Drugs Science Research Doctors 137

The Pharma Data

OCTOBER 29, 2020

If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease. If approved, aducanumab would become the first therapy to reduce the clinical decline in patients with Alzheimer’s disease. CAMBRIDGE, Mass.

Disease 40

Disease Marketing Clinical Trials Treatment 40

The Pharma Data

DECEMBER 9, 2020

(Tokyo, Japan) announced that Biogen has submitted a Japanese New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimer’s disease. Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

Clinical Trials 40

Clinical Trials Drugs Disease Treatment 40

Agency IQ

AUGUST 2, 2024

September 30, 2024 PDUFA Novel Approaches to Development of Cell and Gene Therapy Convene a public meeting to solicit input on methods and approaches (e.g., use of RWE, registries) for capturing post-approval safety and efficacy data for cell and gene therapy products.

FDA 40

FDA Science Regulations Biosimilars 40